The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease who are eligible to receive the drug.

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

Nitisinone, a drug that is already used to treat two genetic diseases, could be repurposed to control the spread of malaria, ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

In Eisai’s main approval trial, almost 33 percent of people with two copies of the gene who got the drug experienced brain swelling compared to just 5 percent of people with no copies.